Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4577379
Max Phase: Preclinical
Molecular Formula: C34H41ClN2O6
Molecular Weight: 609.16
Molecule Type: Unknown
Associated Items:
ID: ALA4577379
Max Phase: Preclinical
Molecular Formula: C34H41ClN2O6
Molecular Weight: 609.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CO[C@H]1/C=C/CCN(C)C(=O)C[C@](O)(C(=O)O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3
Standard InChI: InChI=1S/C34H41ClN2O6/c1-36-15-4-3-7-29(42-2)26-11-8-23(26)19-37-20-33(14-5-6-22-16-25(35)10-12-27(22)33)21-43-30-13-9-24(17-28(30)37)34(41,32(39)40)18-31(36)38/h3,7,9-10,12-13,16-17,23,26,29,41H,4-6,8,11,14-15,18-21H2,1-2H3,(H,39,40)/b7-3+/t23-,26+,29-,33-,34+/m0/s1
Standard InChI Key: LKTGXIUOAGUWFH-GBIPVCRUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 609.16 | Molecular Weight (Monoisotopic): 608.2653 | AlogP: 4.93 | #Rotatable Bonds: 2 |
Polar Surface Area: 99.54 | Molecular Species: ACID | HBA: 6 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 3.49 | CX Basic pKa: 4.74 | CX LogP: 3.58 | CX LogD: 1.53 |
Aromatic Rings: 2 | Heavy Atoms: 43 | QED Weighted: 0.47 | Np Likeness Score: 0.73 |
1. Rescourio G, Gonzalez AZ, Jabri S, Belmontes B, Moody G, Whittington D, Huang X, Caenepeel S, Cardozo M, Cheng AC, Chow D, Dou H, Jones A, Kelly RC, Li Y, Lizarzaburu M, Lo MC, Mallari R, Meleza C, Rew Y, Simonovich S, Sun D, Turcotte S, Yan X, Wong SG, Yanez E, Zancanella M, Houze J, Medina JC, Hughes PE, Brown SP.. (2019) Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere., 62 (22): [PMID:31736296] [10.1021/acs.jmedchem.9b01310] |
Source(1):